Follow-up detection of M-bcr/abl and m-bcr/abl fusion transcripts in chronic myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation.
- Author:
Ya-Zhen QIN
1
;
Yan-Rong LIU
;
Jin-Lan LI
;
Jia-Yu FU
;
Yan CHANG
;
Guo-Rui RUAN
;
Hui WANG
;
Jing-Ying QIU
;
Dao-Pei LU
;
Shan-Shan CHEN
Author Information
1. Institute of Hematology, People's Hospital, Peking University, Beijing 100044, China. hyjq2000@yahoo.com
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Child;
Child, Preschool;
Female;
Follow-Up Studies;
Fusion Proteins, bcr-abl;
genetics;
Hematopoietic Stem Cell Transplantation;
Humans;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
metabolism;
therapy;
Male;
Middle Aged;
RNA, Messenger;
analysis;
Recurrence;
Reverse Transcriptase Polymerase Chain Reaction;
Transplantation, Homologous
- From:
Journal of Experimental Hematology
2003;11(4):368-371
- CountryChina
- Language:Chinese
-
Abstract:
In order to investigate the features of M-bcr/abl and m-bcr/abl fusion transcripts in patients with chronic myeloid leukemia (CML) after allogeneic stem cell transplantation (SCT), M-bcr/abl and m-bcr/abl fusion transcripts were sequentially detected by RT-PCR technique in 72 CML patients after SCT. The results showed that M-bcr/abl positive rate (79.2%, 42/53) within 6 months after SCT was remarkably higher than that in 6-12 months group (34.3%, 11/32) and >or= 12 months group (35.1%, 13/37) (P < 0.001), and the clinical relapse rates in corresponding periods were 1.9% (1/53), 0% (0/32) and 16.2% (6/37) respectively. M-bcr/abl and m-bcr/abl fusion transcripts occurred in 5 of 6 clinically relapsed patients. In period of more than 6 months after transplantation, none of 17 M-bcr/abl(+) samples from 14 patients in cytogenetic remission appeared positive reaction of m-bcr/abl. It is concluded that M-bcr/abl(+) fusion transcript still existed in most patients after SCT, and usually disappeared within 6 months. Existence of M-bcr/abl is not a clinical relapse marker in CML patients. Simultaneous detection of M-bcr/abl and m-bcr/abl fusion transcripts can be helpful for monitoring residual disease.
